Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 2/20 | 0.34 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.31 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.30 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL10588716 | 0.72 | MAOA (0.34) | — | |
| SCHEMBL6780552 | 0.72 | TRPA1 (0.35) | — | |
| SCHEMBL11202182 | 0.72 | NOTUM (0.39) | — | |
| Hydrochloric Acid SCHEMBL10432400 | 0.71 | NOTUM (0.38) | — | |
| SCHEMBL7210084 | 0.70 | — | — | |
| SCHEMBL8775599 | 0.70 | MCL1 (0.40) | — | |
| SCHEMBL28414326 | 0.69 | NOTUM (0.31) | — | |
| SCHEMBL9227676 | 0.68 | GAA (0.33) | — | |
| SCHEMBL9273390 | 0.67 | MCL1 (0.39) | — | |
| Hydrochloric Acid SCHEMBL10435581 | 0.67 | GAA (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3344262-A1 | IMMUNE CELLS HAVING INCREASED IMMUNITY OR RESISTANCE TO AN IMMUNOSUPPRESSIVE CYTOKINE AND USE OF THE SAME | Innate Tumor Immunity, Inc. (US) | 2018-07-11 | — | — | EP | claimed |
| WO-2017040670-A1 | IMMUNE CELLS HAVING INCREASED IMMUNITY OR RESISTANCE TO AN IMMUNOSUPPRESSIVE CYTOKINE AND USE OF THE SAME | IFM THERAPEUTICS, INC (US) | 2017-03-09 | — | — | WO | claimed |
| US-20170056448-A1 | IMMUNE CELLS HAVING INCREASED IMMUNITY OR RESISTANCE TO AN IMMUNOSUPPRESSIVE CYTOKINE AND USE OF THE SAME | IFM THERAPEUTICS, INC (US) | 2017-03-02 | — | — | US | claimed |
| WO-2023091503-A1 | NUCLEIC ACID COMPOSITIONS AND USES THEREOF | SURGE Therapeutics, Inc. (US) | 2023-05-25 | — | — | WO | disclosed |
| EP-3922279-A1 | DRUG DELIVERY COMPOSITIONS AND USES THEREOF | Dana Farber Cancer Institute, Inc. (US) | 2021-12-15 | — | — | EP | disclosed |
| US-20210246211-A1 | DRUG DELIVERY COMPOSITIONS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-08-12 | — | — | US | disclosed |
| US-11021539-B2 | Drug delivery compositions and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| EP-3506884-B1 | DRUG DELIVERY COMPOSITIONS AND USES THEREOF | DANA FARBER CANCER INST INC (US) | 2021-05-05 | — | — | EP | disclosed |
| US-20210059953-A1 | LIPID NANOPARTICLE FORMULATIONS OF NON-VIRAL, CAPSID-FREE DNA VECTORS | GENERATION BIO CO. | 2021-03-04 | — | — | US | disclosed |
| EP-3768236-A1 | COMPOSITIONS AND METHODS FOR CANCER TREATMENT | Dana-Farber Cancer Institute, Inc. (US) | 2021-01-27 | — | — | EP | disclosed |
| US-20210008048-A1 | COMPOSITIONS AND METHODS FOR CANCER TREATMENT | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-01-14 | — | — | US | disclosed |
| US-20190083626-A1 | DRUG DELIVERY COMPOSITIONS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-03-21 | — | — | US | disclosed |
| WO-2019051289-A1 | LIPID NANOPARTICLE FORMULATIONS OF NON-VIRAL, CAPSID-FREE DNA VECTORS | GENERATION BIO CO. (US) | 2019-03-14 | — | — | WO | disclosed |
| EP-3344262-A1 | IMMUNE CELLS HAVING INCREASED IMMUNITY OR RESISTANCE TO AN IMMUNOSUPPRESSIVE CYTOKINE AND USE OF THE SAME | Innate Tumor Immunity, Inc. (US) | 2018-07-11 | — | — | EP | disclosed |
| WO-2018045058-A1 | DRUG DELIVERY COMPOSITIONS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-03-08 | — | — | WO | disclosed |
| WO-2017040670-A1 | IMMUNE CELLS HAVING INCREASED IMMUNITY OR RESISTANCE TO AN IMMUNOSUPPRESSIVE CYTOKINE AND USE OF THE SAME | IFM THERAPEUTICS, INC (US) | 2017-03-09 | — | — | WO | disclosed |
| US-20170056448-A1 | IMMUNE CELLS HAVING INCREASED IMMUNITY OR RESISTANCE TO AN IMMUNOSUPPRESSIVE CYTOKINE AND USE OF THE SAME | IFM THERAPEUTICS, INC (US) | 2017-03-02 | — | — | US | disclosed |
| US-4051247-A | ANTIBACTERIAL AGENTS | RIKER LABORATORIES, INC. (US) | 1977-09-27 | — | — | US | disclosed |
| US-3985753-A | ANTIBACTERIAL AGENTS | RIKER LABORATORIES, INC. (US) | 1976-10-12 | — | — | US | disclosed |
| US-3976651-A | BACTERICIDE | RIKER LABORATORIES, INC. (US) | 1976-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210008048-A1 | COMPOSITIONS AND METHODS FOR CANCER TREATMENT | STING1, IL15, MAPK15 | SRD5A2 3822/4885SRD5A1 2672/4885CTDSP1 2331/4885 |
| US-20190083626-A1 | DRUG DELIVERY COMPOSITIONS AND USES THEREOF | STING1, IL15, IL15RA | SRD5A2 2405/4885SRD5A1 1296/4885CTDSP1 2579/4885 |
| US-20210059953-A1 | LIPID NANOPARTICLE FORMULATIONS OF NON-VIRAL, CAPSID-FREE DNA VECTORS | HDLBP, POLN, NPC1 | SRD5A2 4806/4885SRD5A1 4765/4885CTDSP1 115/4885 |
| US-20170056448-A1 | IMMUNE CELLS HAVING INCREASED IMMUNITY OR RESISTANCE TO AN IMMUNOSUPPRESSIVE CYTOKINE AND USE OF THE SAME | IL2, IFNG, IL2RA | SRD5A2 2581/4885SRD5A1 2725/4885CTDSP1 4642/4885 |
| US-20210246211-A1 | DRUG DELIVERY COMPOSITIONS AND USES THEREOF | STING1, IL15, IL15RA | SRD5A2 2405/4885SRD5A1 1296/4885CTDSP1 2579/4885 |
| US-11021539-B2 | Drug delivery compositions and uses thereof | STING1, IL15, IL15RA | SRD5A2 2405/4885SRD5A1 1296/4885CTDSP1 2579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.